European Biotech Acquisition Corp. Units
EBACU
EBACU was delisted on the 2nd of March, 2023.
30 hedge funds and large institutions have $32.3M invested in European Biotech Acquisition Corp. Units in 2021 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 4 increasing their positions, 4 reducing their positions, and 8 closing their positions.
0% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 4
19% less funds holding
Funds holding: 37 → 30 (-7)
27% less capital invested
Capital invested by funds: $44.6M → $32.3M (-$12.2M)
88% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 8
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SMA
Sage Mountain Advisors
Atlanta,
Georgia
|
+$740K |
| 2 |
WC
Wealthspring Capital
West Harrison,
New York
|
+$400K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$8.73K |
| 4 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$1.47K |
| 5 |
Jane Street
New York
|
+$20 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
-$3.78M |
| 2 |
ACA
Arena Capital Advisors
Los Angeles,
California
|
-$2.26M |
| 3 |
BCM
BlueCrest Capital Management
St Helier,
Jersey
|
-$2M |
| 4 |
PCM
Pentwater Capital Management
Naples,
Florida
|
-$1.49M |
| 5 |
CCM
CAAS Capital Management
New York
|
-$999K |
EBACU Hedge Fund Activity: Q3 2021 in Review
30 of the 5,729 institutional investors tracked by Wall St. Rank reported a position in European Biotech Acquisition Corp. Units (EBACU) for Q3 2021, worth a combined $32.3M — down 27% from $44.6M a quarter earlier.
Sellers outnumbered buyers: 8 funds closed out of EBACU and 1 opened new positions — a net loss of 7 holders — while 4 trimmed existing stakes and 4 added.
The largest buyer was Sage Mountain Advisors, adding an estimated $740K. The largest seller was Macquarie Group, exiting entirely with an estimated $3.78M sold.
- 30 institutional investors held European Biotech Acquisition Corp. Units (EBACU) as of Q3 2021, down from 37 in Q2 2021.
- Funds reported $32.3M of European Biotech Acquisition Corp. Units stock for Q3 2021, down 27% quarter-over-quarter.
- 1 fund opened new European Biotech Acquisition Corp. Units positions in Q3 2021 and 8 closed out, a net change of -7 holders.
- The largest European Biotech Acquisition Corp. Units buyer in Q3 2021 was Sage Mountain Advisors, an estimated $740K added.
- The largest European Biotech Acquisition Corp. Units seller in Q3 2021 was Macquarie Group, an estimated $3.78M sold.
Based on aggregated 13F filings for Q3 2021.